MarketInOut Stock Screener Log In | Sign Up
 

Cytokinetics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/10/2026 16:00
Cytokinetics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization10,489 mln
Float91.07 mln
Earnings Date10/29/2026

Piotroski F-Score

1 / 9
Very weak

Beneish M-Score

-0.53
Highly suspicious

1-Year Forecast

110
Exceptional upside

Relative Strength

22 / 100
Significantly lagging

Debt / Equity

-7.32
Negative equity

Pre-Tax Margin

-1,321%
Severely loss-making

Business Description

Cytokinetics is a US-based drug development company focused on creating medicines that target muscle function to treat serious heart and muscle diseases. Its lead product, MYQORZO, is an approved oral treatment for a condition where the heart muscle becomes abnormally thick and obstructed, and the company has several other drugs in various stages of clinical testing that aim to address different forms of heart failure. Founded in 1997 and based in South San Francisco, Cytokinetics is working to build a portfolio of treatments for patients with few existing options.

Key Fundamentals

EPS-7.22
RPS0.54
ROIC-117
ROA-61.36
EBITDA, mln-757
EV / EBITDA-13.38
EV / EBIT-13.17
Revenue, mln67.67
EV / Revenue150

Financial Strength

Altman Z-Score-0.61
Piotroski F-Score 1 / 9
Beneish M-Score-0.53
1-Year Target Price110
Short Ratio8.95
Short % of Float17.92

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 2.35% 86 / 100   
1 Month -3.7% 36 / 100   
2 Months 4.12% 73 / 100   
6 Months 15.7% 76 / 100   
1 Year 42.95% 87 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us